Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study

Axel Petzold, Martijn D Steenwijk, Judith M Eikelenboom, Mike P Wattjes, Bernard MJ Uitdehaag
2016 Multiple Sclerosis  
Body fluid and structural imaging biomarkers give information on neurodegeneration.The relationship over time is not known in multiple sclerosis. Objective To investigate the temporal relationship of elevated cerebrospinal fluid (CSF) neurofilament protein (Nf) levels, a biomarker for axonal loss, with magnetic resonance imaging (MRI) atrophy measures. Methods In patients with multiple sclerosis CSF Nf heavy chain phosphoform levels were quantified at baseline and dichotomised into 'normal' and
more » ... 'high'. Atrophy was assessed by MRI at baseline and 15-year follow-up using SIENAX and FreeSurfer software. Results High baseline CSF NfH-SMI35 levels predicted pronounced atrophy at 15year follow up (OR 36, p<0.01), in absence of baseline brain atrophy (OR 28, p<0.05), for the averaged MRI normalised brain volume (1.44 L vs 1.33 L, p<0.05), normalised grey matter volume (0.77 L vs 0.69 L, p<0.01) and putamen (12.7 mL vs 10.7 mL, p<0.05). Region specific calculations including the spinal cord showed that a power of >80% is reached with 14-50 patients. Conclusion These data suggest that high CSF NfH levels are an early predictor of later brain and spinal cord atrophy using structural imaging biomarkers and can be investigated in reasonably sized patient cohorts. Prepared using sagej.cls
doi:10.1177/1352458516645206 pmid:27207456 fatcat:ovwq7anrijg3zcydqis5s6kvm4